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Kümmel: The timing of SNB in the neoadjuvant setting is still 
unclear. How useful could SLN surgery be in avoiding the 
more invasive formal axillary node dissection? The ACOSOG 
Z1071 trial, presented by Boughey et al., investigated the 
question, whether SNB after NAC is an accurate and feasible 
method. 689 patients with T0–4, histologically proven N1–2, 
M0 status were enrolled. Of 639 patients with identified SLN, 
the detection rate was 92.7% and 40% of the patients had a 
complete pathologic remission. The FNR with at least 2 SLN 
examined were 12.6%, for 1 SLN resected it was 31.5%. The 
conclusion of this important study: SNB will enable a reduc-
tion in the extend of axillary surgery if dual tracers are used 
and at least 2 SLN are examined after NAC. But the sentinel 
concept is not based on the model to resect a minimum of 
2 SLN and for the FNR we should also take into considera-
tion the rate of unidentified SLN of 7.3%.
The German SENTINA trial, presented by Kühn et al., is a 
4-arm study with over 1,700 enrolled patients from 103 institu-
tions. 50.8% of the enrolled patients were cN0 – after SNB 
35.2% were pN1 prior to NAC. In the population of cN1 
(41.2%) only 20% were histologically proven. The detection 
rate prior to any therapy was 99.1% – indicating the high 
quality of this multicenter surgical trial. However, after SNB 
and NAC the detection rate was only 60.8%; in patients with 
cN1 status without prior SNB it was 80.1%. For patients with 
pN1 (SNB = pN1 – NAC – Re-SNB – axillary lymph node 
 dissection, ALND) the FNR was 51.6% – for patients with 
cN1 (no prior SNB – NAC – SNB – ALND) the FNR was 
14.2%. Therefore it was concluded from this up to date  largest 
prospective trial that in patients who convert under NACT 
from cN1 to cN0 SNB as a diagnostic procedure is not as 
 reliable as SNB in primary surgery.
Question 1: Breast Cancer Surgery – Which New 
 Findings with Clinical Implications Did You See?
Fehm: The role of sentinel lymph node biopsy (SNB) in 
 patients receiving neoadjuvant chemotherapy (NAC) is still 
unclear. 2 abstracts investigated the feasibility and false nega-
tive rates of SNB in the neoadjuvant setting. The German 
SENTINA (SENTInel NeoAdjuvant) trial presented by Kühn 
et al. (S2–2) was a 4-arm prospective multicenter cohort study 
designed to evaluate a specific algorithm for the timing of a 
standardized sentinel lymph node (SLN) procedure in pa-
tients who undergo NAC and to provide reliable data for the 
detection rate (DR) and false negative rate (FNR) in different 
settings. 1,737 eligible patients from 103 institutions were 
 enrolled in this trial. The DR for SNB was 99% before NAC 
in clinically node negative patients, 80% in clinically node 
positive patients receiving SNB after NAC, and 61% after 
prior SNB and NAC. The SNB was false negative in 14% of 
patients with cN1/ycNo and SNB after NAC and 52% in 
 patients with re-SNB after NAC. The clinical consequences 
from these data are that SNB should be performed in cN0 
 patients before NAC. In cN1 patients who convert to ycN0, 
SNB is lacking accuracy and should not be performed. 
The ACOSOG trial Z1071 presented by Boughey et al. 
(S2–1) investigated the role of SNB in 689 patients with clini-
cally positive lymph nodes after NAC. 756 patients were en-
rolled from 136 institutions. SNB correctly identified the 
nodal status in 84% of the 695 patients and was associated 
with an FNR of 12.8%. The FNR could be reduced if at least 
2 SN were removed and a dual tracer method was applied. 
However, the first suggestion to reduce the FNR cannot be 
implemented in clinical routine since in many cases patients 
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staging following NAC is undoubtedly demonstrated SNB fol-
lowing NAC should not applied as part of clinical routine.
Rack: The SENTINA trial evaluated nodal surgery in both 
clinically node-negative and node-positive disease. The use-
fulness of primary sentinel node excision in cN0 disease be-
fore the start of systemic treatment is confirmed by this trial. 
Both trials evaluate the optimal surgical procedure in cN1 pa-
tients. SNB after preceding lymph node surgery and systemic 
treatment in cN1 patients has an unacceptably high false 
 negative rate of 51.6%, and is therefore no reasonable option. 
In cN1 patients only receiving preoperative chemotherapy 
but no previous SNB, the false negative rate is still higher 
than in patients with cN0: 14.2% (SENTINA) and 31.5% 
(ACOSOG). While Kühn et al. concluded that SNB is not a 
reliable diagnostic tool in cN1 patients, Boughey et al. consid-
ered SNB an option under special circumstances, i.e. in pa-
tients with good clinical response, using dye and a radioactive 
tracer, if > 3 lymph nodes are removed and a clip is placed at 
fine needle aspiration.
Steger: The results of 2 clinical trials dealing with the timing of 
sentinel node biospy in regard to NAC were presented. These 
prospective trials investigated mainly the detection rates and 
the FNRs of the sentinel node(s) and were similar in design 
though not identical. Of interest is the fact that even though 
the results were also rather similar with a false negative rate 
of 14% in the large German SENTINA trial (n = 1,737) und 
12.8% in the ACOSOG Z1071 (n = 756), the conclusions 
drawn by the authors were exactly the opposite: while the 
German group concluded that this FNR of the SNB is too 
high after neoadjuvant treatment and cannot be recom-
mended for routine use, the presenter of the ACOSOG trial 
did just that. I think that based on these results no clear and 
firm conclusions can be drawn at the moment and thus it is 
too early to recommend this procedure for the daily practice. 
Further clinical investigations should focus on modifications 
of the SNB procedure.
Question 2: Triple Negative Breast Cancer:  
Which New Aspects of Treatment Might Lead  
to Progress in the Clinical Management?
Fehm: Bevacizumab is an approved therapeutic option in 
HER2 negative metastatic breast cancer. A potential role was 
discussed for bevacizumab in the adjuvant setting for triple 
negative breast cancer (TNBC) patients. The BEATRICE 
trial was designed to test this hypothesis (S6–5). In this open-
label randomized multinational phase III trial, patients with 
TNBC were randomized to receive ≥ 4 cycles of either chemo-
therapy (CT) alone or the same CT + 1 year of bevacizumab 
5 mg/kg/wk equivalent. There was no statistically significant 
improvement in disease free survival (DFS) with the addition 
Liedtke: To my opinion, the most important data regarding 
breast cancer surgery at this year’s SABCS 2012 was that 
 regarding axillary staging in the context of NAC. SLNB prior 
to NAC is associated with a reliable and accepted accuracy 
and a low false-negative rate, whereas SNB following NAC 
has the potential to spare patients who are downstaged from a 
positive to a negative lymph node status from further regional 
treatment.
First, the Z1071 study of the American College of Sur-
geons Oncology Group (ACOSOG) analyzed data of 637 
women with pathologically positive axillary nodes at primary 
diagnosis who underwent neoadjuvant chemotherapy. Pa-
tients then underwent SNB and secondary ALND. The 
 authors stated that at least 2 SLN needed to be taken out. 
A detection rate of 92.7% (95% confidence interval (CI) 
90.5–94.6) was reported. 40% of patients converted from 
pathologically positive lymph nodes prior to NAC to a histo-
logically negative axilla (n = 255). Among the 382 patients 
(60%) who did show residual invasive tumor cells in the axil-
lary nodes, 56 patients had a negative SNB but were found to 
be node positive upon ALND. This translated into an accu-
racy of 91.2% for SNB following NAC. Among patients who 
had at least 2 SLNs excised following NAC, an FNR of 12.6% 
was reported (95% CI 9.4–16.7%). However, an FNR of 
31.5% was reported among patients who had only one SLN 
taken out at the time of axillary staging. The authors con-
cluded that SNB following NAC would be a useful method 
for axillary staging provided that 2 SLN be taken out and a 
dual tracer (i.e. blue dye and radiolabelled colloid) be used.
These results are in contrast to the results from the Ger-
man SENTINA trial. In this trial, patients undergoing axillary 
staging in the context of NAC were recruited to 4 study arms 
based on clinical nodal status before and after NAC. One arm 
containing 592 patients was largely similar to the study popu-
lation of ACOSOG Z1071. In this trial a conversion rate of 
52.3% from cN1 before NAC to pN0 following NAC was 
 reported. In contrast to the results of Z1071 an FNR of 14.2% 
was reported in the study arm resembling ACOSOG Z1071 
and an even higher rate of 51.6% was found among patients 
undergoing one SNB prior to and a second one after NAC. 
The authors of this trial concluded that the FNR for a re-
peated SNB after NAC would be unacceptable. Also the FNR 
for patients who are downstaged through NAC from a posi-
tive to a negative axillary status would appear less favorable 
compared to the FNR initially reported in the context of pri-
mary surgery. Therefore, in this study, SNB as a diagnostic 
procedure was not found to be a reliable tool in patients who 
convert under NAC from cN1 to cN0 compared to SNB in 
primary surgery and should therefore be omitted.
At this point we have to wait until further results and more 
details regarding the methodology of these trials are being re-
ported before a final judgement can be made based on these 
data. Further trials evaluating this context are currently being 
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BW 3-weekly). However, the primary endpoint of this study 
could not be reached as the IDFS rates in both study arms 
were not significantly different (82.7% (95% CI 80.5–85.0) vs. 
83.7% (95% CI 81.4–86.0), respectively, hazard ratio (HR) 
0.87, p = 0.18). Not surprisingly, there was no significant ben-
efit as to overall survival in both arms. Toxicities were as can 
be expected in the context of combination chemotherapy and 
bevacizumab. Therefore, bevacizumab does not seem to be 
the optimal candidate for a novel adjuvant treatment option 
for patients with TNBC. Further trial results of bevacizumab 
in the adjuvant setting among patients with TNBC have to be 
awaited (e.g. NSABP-B46, www.clinicaltrials.gov).
However, despite these disappointing data, several trans-
lational and basic science analyses were presented that pro-
vided a rationale for the use of anti-myc-targeted agents 
(Goga et al.) or a combination approach of inhibitors of the 
HDAC together with inhibition of PARP function (Bhalla 
et al.). Balko et al. presented results of a systematic analysis 
of tumor tissue derived from 114 clinically defined TNBC 
 patients who presented with residual tumor burden following 
NAC. These tumors were analyzed using immunohistochem-
istry (112/114), next generation sequencing (81/114) and gene 
expression (89/114). The authors hypothesized that at least 
5 targetable signaling pathways were present among these 
 tumors, i.e. PI3K/mTOR inhibition, receptor tyrosine kinase 
inhibitors, DNA repair targeting agents, cell cycle/mitotic 
spindle inhibitors, and RAF/MEK inhibitors. The authors 
 regard their results as a ‘targetable catalogue’ of the altera-
tions present in the residual disease of TNBC after NAC. As 
to how these results may be translated into clinical practice 
remains to be demonstrated. 
Rack: Of interest, albeit negative, were the results from the 
BEATRICE trial: there is no benefit for TNBC patients from 
the addition of bevacizumab to adjuvant anthracycline and 
taxane based chemotherapy in the whole study population or 
in any subgroup. Also the results from the LEA trial were 
negative: the investigators found no benefit from the addition 
of bevacizumab to letrozole or fulvestrant in the first-line 
treatment of metastatic patients. Therefore unfortunately no 
progress has been made so far for triple negative patients.
Steger: I am afraid, no practice-changing results were presented! 
The negative results of the large adjuvant BEATRICE trial 
showing no significant benefit for patients receiving chemo-
therapy and adjuvant bevacizumab for 1 year are very dis-
appointing. Even though there was a small numerical reduc-
tion in events during the bevacizumab treatment with maybe 
a short ‘carry over effect’, this trial has to be judged to be 
 negative. From a biostatistical point of view there might still 
be a small chance for the secondary study endpoint ‘overall 
survival’ to come up with a positive result, but this chance is 
very small and it is projected that these results are maybe 
available at the ASCO meeting 2013. As always, data from 
of 1 year bevacizumab to adjuvant CT for TNBC, underlining 
the limited clinical role of bevacizumab in breast cancer (un-
less valid predictive biomarkers can be identified).
An important strategy to identify new targetable alterations 
in patients with TNBC may be the molecular profiling of re-
sidual tumor tissue after primary systemic therapy. Balko et al. 
(S3–6) demonstrated in their study that approximately 90% of 
these patients had aberrations in pathways (e.g. DNA repair, 
PI3K/mTOR, ras/MAPK9) which can already be targeted or 
for which targeted drugs are in development leaving hope for 
the optimization of treatment for TNBC patients.
Kümmel: The BEATRICE trial, presented by Cameron et al., 
evaluated in a phase III prospective setting the role of 1 year 
adjuvant bevacizumab in triple negative patients (centrally 
confirmed). In terms of primary endpoint – invasive disease 
free survival (IDFS) for the 2,591 randomly assigned patients, 
the 3-year rates were 82.7% for patients with anthracyline 
and/or taxan-based chemotherapy without bevacizumab vs. 
83.7% with addition of bevacizumab. The subgroup analysis 
revealed no strong signal in any subpopulation. Another hope 
is to discriminate patients who benefit from an anti-angio-
genesis strategy in the early phase of breast cancer. Therefore 
Carmeliet et al. presented the biomarker analysis of this 
study. Unlike other trials in the metastatic setting (AVADO, 
AVEREL), the baseline pVEGF A level showed no pre-
dictive value in the adjuvant microenvironment and only a 
small population of patients with high levels of baseline 
pVEGFR 2 had a benefit from the addition of bevacizumab. 
For this aggressive tumor biology there seems to be no addi-
tional therapy option to date. 
Promising in vitro results were presented by Bhalla and 
colleagues indicating that pan-histone-deacetylase (HDAC) 
inhibitors can sensitize TNBC cells for poly-A-ribose poly-
merase (PARP) inhibitors and alkylating cytotoxic agents 
 independent of BRCA mutation status. Another approach is 
to evaluate molecular alterations in patients with TNBC after 
NAC and residual disease. As known so far, these patients 
have a significantly poorer prognosis. Balko et al. demon-
strated that 90% of these tumors had an aberration in PI3K/
mTor, DNA repair (BRCA1/2), Ras/MAPK, cell cycle, or 
GFR pathways. The pathway which is affected could be the 
goal for additional targeted therapy.
Liedtke: As the use of bevacizumab seems to be beneficial for 
patients with TNBC in both the neoadjuvant and the meta-
static setting, the results of the BEATRICE trial evaluating 
the use of bevacizumab among patients with TNBC in the 
 adjuvant setting have long been awaited with interest. In this 
trial patients with TNBC having undergone primary curative 
breast and axillary surgery were randomized to either chemo-
therapy alone (4–8 cycles based on investigator’s choice) or 
in combination with infusions of a 5 mg/kg body weight 
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the pertuzumab arm (HR = 0.52; 95% CI 0.31−0.86; p = 0.0098 
(Miles et al.). In a first translational analysis of the expression / 
function of HER2 pathway components predicting particular 
benefit from pertuzumab, no clear predictive biomarker could 
be identified (Baselga et al.). These results underscore the 
therapeutic importance of pertuzumab in the treatment of 
HER2+ breast cancer.
Rack: The ATLAS (Adjuvant Tamoxifen: Longer Against 
Shorter) study showed a benefit from 5 vs. 10 years of 
tamoxifen in a large randomized trial with long follow-up. 
These  results should be translated into clinical practice in 
 premenopausal patients or in case of contraindications 
against aromatase inhibitors. A confirmatory analysis of the 
CLEOPATRA trial shows an advantage in PFS and OS for 
patients treated with first-line pertuzumab + trastuzumab + 
docetaxel for MBC. The combined HER2 blockade will be-
come the new standard of care. 1 year of trastuzumab in early 
breast cancer was confirmed as best standard of care by 
 several trials. Also the oral CDK46 inhibitor PD 0332991 
shows very promising results in postmenopausal ER+HER2– 
in an interim analysis of a small phase II trial with very limited 
side effects. However, confirmatory trials are needed.
Steger: The pertuzumab data from the CLEOPATRA trial 
showing a significant survival benefit for HER2+ patients will 
for sure change our way to treat these patients in the clinical 
routine. It is expected that pertuzumab will be available soon 
for this indication. Also, the adjuvant evaluation is still on-
going (APHINITY trial) which might also lead to a change in 
clinical practice when positive. Also the data from the trastu-
zumab-emtansine (T-DM1) trials are very promising that the 
possibilities to treat HER2+ breast cancer in advanced  disease 
might change to even more effective treatments with a good 
and low toxicity profile. Moreover, results from a randomized 
phase II trial with the CDK 4/6 inhibitor PD0332991 in ER+/
HER2– patients show that this approach may also influence 
overall survival and thus phase III trials are urgently needed 
and are already set up.
Question 4: Which of the Presented Data on  
Adjuvant and Neoadjuvant Chemotherapy  
Will Be Applied in Your Clinical Routine?
Fehm: The 10-year survival follow-up of the AGO trial IDD-
ETC presented by Moebus et al. (S3–4) confirmed the role of 
intense dose-dense (IDD) regimens in high-risk breast cancer 
patients with at least 4 positive nodes. In the experimental 
arm, patients were assigned to receive 3 courses each of epi-
rubi cin (150 mg/m2), paclitaxel (225 mg/m2) and cyclophospha-
mide (2,500 mg/m2) at 2-week intervals with G-CSF support. 
In the standard arm 4 courses of conventionally dosed epi rubi-
cin / cyclophosphamide (90/600 mg/m2) followed by 4 courses 
several preclinical studies were presented which might give 
new insights for the treatment of basal-like or TNBC but it 
does not appear that these data will lead to a change in the 
clinical management soon.
Question 3: Which New Developments in Targeted 
Therapies of Breast Cancer Will Find Their Way  
Into Practice?
Fehm: PD 0332991 is an oral, highly selective inhibitor of 
 cyclin dependent kinase (CDK)4/6 activity and prevents 
 cellular DNA synthesis by inhibiting progression of cell cycle 
from G1 to S phase. Preclinical data revealed that PD 0332991 
may be particularly effective in the luminal subtype of breast 
cancer. Finn et al. (S1–6) presented the results of a phase II 
study comparing letrozole alone versus letrozole in combina-
tion with PD 0332991 for first-line treatment of estrogen re-
ceptor (ER)+/HER2– advanced breast cancer. The combina-
tion showed a statistically significant improvement in median 
progression-free survival (PFS) (26.1 vs. 7.5 months). The com-
bination was well tolerated with uncomplicated neutro penia 
as the most common adverse event. Due to the promising re-
sults, a randomized phase III study is planned to start in 2013.
Kümmel: Cyclin dependent kinases play their role in regulat-
ing cell cycle progression. The orally given PD 0332991 is a 
highly selective inhibitor of CDK4/cyclin D1 and CDK6/ 
cyclin D2 as recently presented at the SABCS meeting by 
Finn et al. Their results of a phase II study revealed promising 
data in patients with ER+/HER2– metastatic breast cancer. 
In combination with letrozole (n = 84) the median PFS was 
26.1 months vs. 7.5 months for letrozole given alone (n = 81) 
with a clinical benefit rate of 70% vs. 44%. These important 
data will be further investigated in phase III trials and should 
then be translated as soon as possible into trials for treatment 
of early breast cancer patients.
Liedtke: To my opinion, the most striking results in the 
 context of novel therapies was the study of PD 0332991, as 
mentioned by Drs. Fehm and Kümmel. Also, several analyses 
of the CLEOPATRA study, a randomized, double-blind, 
 placebo-controlled phase III study of first-line treatment with 
pertuzumab, trastuzumab, and docetaxel in patients with 
HER2+ metastatic breast cancer (MBC) showed that the use 
of pertuzumab resulted in a statistically significant and clini-
cally highly meaningful improvement of overall survival (OS) 
with a HR of 0.66 (95% CI 0.52−0.84). The median OS in the 
standard arm was 37.6 months whereas for patients in the ex-
perimental arm it has not yet been reached (Swain et al.). In 
another analysis, a benefit of pertuzumab in the subgroup of 
patients aged ≥ 65 years was investigated. A PFS benefit in 
this subgroup of patients could clearly be reached: median 
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(639 vs. 722, p = 0.01). This benefit was observed particularly 
more than 10 years after initiation of adjuvant therapy. 
The relative risk of breast cancer mortality was 0.97 (95%CI 
0.79–1.18) after 5–9 years and 0.71 (95%CI 0.58–0.88) after 
more than 10 years. If these results are added to the results 
seen after 5 years of adjuvant tamoxifen one may summarize 
that 10 years of tamoxifen lead to a reduction in breast cancer 
mortality of 30% within the first decade and of about 50% 
in the second decade following initiation of therapy. The 
 German national guidelines have not yet commented on these 
results. Also, the results have to be seen in the context of 
 extended adjuvant therapy with 5 years of tamoxifen followed 
by 5 years of aromatase inhibition, which may result in a 
higher therapeutic index given a change in the toxicity spec-
trum. However, up to this point, extended adjuvant therapy 
may be an option particularly in the context of contraindica-
tions against the use of aromatase inhibitors.
Rack: The data from the IDD-ETC trial are confirmatory and 
show clinical benefit for dose-dense treatment in high-risk 
 patients. This should be translated into clinical practice.
Steger: The data which will for sure change daily clinical prac-
tice immediately are those for the long-term use of tamoxifen 
in patients with hormone-sensitive tumors. The presented 
data of the very large ATLAS trial show very clearly that 
tamoxifen for 10 years instead of only 5 years leads to a sig-
nificant reduction of risk for all 3 clinically relevant endpoints, 
i.e. DFS, breast cancer specific survival, and OS. To me it is of 
note that these results were seen particularly in women who 
were premenopausal at the time of diagnosis and that this 
benefit occurred as late as during the third quinquennium of 
follow-up, showing how important long-term observation is 
for clinical trials as well as for our routine patients in order to 
detect late recurrences. The metaanalysis of the German neo-
adjuvant trials clearly show how bad the prognosis of young 
women (≤ 35 years at diagnosis) really is; but the results also 
show how well these patients respond to neoadjuvant treat-
ment. This higher rate of complete pathological responses was 
not only seen in patients with triple-negative but also in pa-
tients with hormone-sensitive disease. For me these data are 
very valuable since they show that neoadjuvant chemotherapy 
in young patients with tumors of the luminal subtype really 
does make sense and should therefore been offered to these 
patients if neoadjuvant treatment is indicated.
Question 5: ‘Trials in Progress’ Session: What Are 
 Important Breast Cancer Trials Currently Recruiting?
Fehm: In this year, several ongoing trials were presented in-
vestigating the clinical role of circulating tumor cells (CTCs) 
in the metastatic setting. The German DETECT III trial 
(www.detect-studien.de) (OT1–1–10) is a randomized, open-
of paclitaxel (175 mg/m2) were given (EC → T, q3w). The sur-
vival rate was 69% in the IDD arm versus 59% in patients 
treated with standard chemotherapy. The application of  epoetin 
alfa in the IDD-ETC arm had no impact on DFS and OS.
Loibl et al. (S3–1) presented the results of the pooled  analysis 
of neoadjuvant trials for the subgroup of very young patients 
(age ≤ 35 years). The pCR rate was significantly higher in the 
very young than in the group > 35 years (23.6% vs. 15.7.%; 
p < 0.0001). This effect was mainly seen in the  triple negative 
group. Interestingly, in comparison to other analyses, very 
young patients with luminal subtype benefit from a pathologi-
cal complete response and should therefore be considered for 
neoadjuvant treatment
Kümmel: In the adjuvant setting, Moebus et al.; presented the 
10-year DFS and OS analysis for high-risk early breast cancer 
patients with ≥ 4 positive LN. In this randomized phase III 
trial with 1,284 patients with a median number of 8 involved 
lymph nodes, the 6-cycle IDD-ETC regimen showed a signifi-
cant overall survival advantage (69% vs. 59%) for patients 
treated with 8 cycles of EC followed by paclitaxel 3-weekly. In 
accordance with these data IDD-ETC should be considered 
as a standard regimen for high-risk breast cancer patients with 
node positive disease (≥ 4 involved LN).
In patients with local and regional recurrences, Aebi and 
colleagues presented an intergroup study (CALOR – Chemo-
therapy as Adjuvant for Locally Recurrent Breast Cancer). 
This is the first randomized study that shows that patients 
benefit from adjuvant or extended adjuvant chemotherapy, 
a clinically widely accepted routine, with the main effect in 
the ER– situation (5-year OS 88% CT vs. 76% no CT, p 0.02). 
Unfortunately, the trial was closed prematurely with only 
162 randomized patients because of a low accrual rate. In the 
neoadjuvant situation, Loibl et al. presented the data from the 
AGO-B, GBG neoadjuvant metaanalysis (overall n = 8,949) 
for the subgroup of very young patients ≤ 35 years (n = 704). 
The more aggressive biology and poorer survival is known 
but in contrast to further analysis for all patients, very young 
patients with ER+/HER2– tumors benefit from a pCR 
and these patients should be considered for (neo)adjuvant 
chemotherapy.
Liedtke: With regard to adjuvant chemotherapy, to my opin-
ion the most important results were those of extended adju-
vant tamoxifen therapy (10 instead of 5 years) among patients 
with hormone receptor-positive breast cancer. The ATLAS 
study is a randomized phase III trial of 6,846 women that have 
been randomized to receive an additional 5 years of tamoxifen 
following 5 years of adjuvant tamoxifen therapy vs. none. 
After a median follow-up of 8 years, the authors demon-
strated a significant improvement regarding all 3 survival end-
points, i.e. disease recurrence (617 vs. 711, p = 0.002), breast 
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Steger: Many trials have been presented which are currently 
ongoing or will be opened within 2013. I think that most of 
them are interesting and promising but we will only know 
which ones are really important once the results are presented!
Question 6: Did You Find Further Aspects  
of Relevance?
Fehm: Two important studies have to be mentioned. The 
ATLAS trial (S1–2) demonstrated that the clinical outcome 
of patients receiving 10 years tamoxifen is improved com-
pared to those with 5 years tamoxifen. Therefore, particularly 
in premenopausal patients 10 years tamoxifen might be an 
 important option as extended adjuvant treatment. The data 
of the CALOR trial (S3–2) presented by Aebi et al. demon-
strated that chemotherapy should be offered to hormone 
 receptor negative patients with local recurrence since this 
 subgroup of patients showed a significant benefit from sys-
temic cytotoxic treatment.
Kümmel: Hypofractionated postsurgery radiation (40 Gy in 
15 fractions vs. conventional 50 Gy in 25 fractions) to treat 
early breast cancer patients was investigated in the UK in the 
START B trial, presented by Haviland et al., with a follow up 
of 10 years (n = 2,215). They conclude that the 15-fraction 
(3 weeks) radiotherapy is gentler on normal tissue and non-
inferior to a conventional 25-fraction (5 weeks) schedule and 
therefore standard of treatment in UK for all patients with 
 invasive breast cancer. Earlier trials did not show a benefit of 
longer administration of tamoxifen. Davies and colleagues on 
behalf of the ATLAS trial group showed in ER+ disease an 
overall benefit of extending tamoxifen from 5 to 10 years 
(6,846 patients who had completed 5 years of tamoxifen were 
randomized; RR 0.79, p 0.01). Patients who are still premeno-
pausal after 5 years of tamoxifen and are not candidates for 
an AI according to the MA.17 trial, have a benefit from a 
longer duration of tamoxifen treatment.
Liedtke: Several researchers analyzed the value of gene 
 expression profiling indices in the context of prediction of late 
metastases among patients with hormone receptor positive 
breast cancer (Dubsky et al.; Sgroi et al.). These authors could 
demonstrate that several genomic tools designed to predict 
disease recurrence within 5 years do also predict late recur-
rence between 5 and 10 years after primary results. These 
 results not only add to the body of evidence supporting the 
use of genomic tools in risk stratification of patients of hor-
mone receptor positive breast cancer but also suggest that late 
metastases may not be that biologically distinct from early 
metastases as we have thought. Another interesting study was 
the CALOR trial (Chemotherapy as Adjuvant for Locally 
Recurrent Breast Cancer). Many clinicians tend to use an 
 adjuvant chemotherapy regimen for patients with locore-
label, 2-arm phase III study comparing standard treatment 
alone vs. standard treatment plus HER2-targeted therapy with 
lapatinib in HER2-negative metastatic breast cancer patients 
with HER2-positive CTCs. Choices of chemotherapy and en-
docrine therapy include: docetaxel, paclitaxel, capecitabine, 
vinorelbine, non-pegylated liposomal doxorubicin, letrozole, 
exemestane, and anastrozole. The aim of the French STIC 
trial (OT3–4–06) is to evaluate the use of CTCs to  determine 
the disease aggressiveness and the choice of first-line treat-
ment in potentially hormone sensitive MBC. First-line MBC 
patients will be randomized between the clinician’s choice and 
CTC count-driven choice. In the CTC arm, patients with 
≥ 5 CTC/7.5 ml will receive chemotherapy whereas patients 
with < 5 CTC/7.5 ml will receive endocrine therapy as first-
line treatment. In the CirCe01 trial (OT3–4–05) 304  metastatic 
breast cancer patients will be randomized between the stand-
ard arm, in which the treatment management is made follow-
ing the current standard of care, and the CTC-driven arm, in 
which the ‘response’ after every first cycle of any new chemo-
therapy line is assessed by CTC count before the second cycle. 
Kümmel: The most interesting trials are studies with focus on 
personalized treatment strategy: The ADAPT (Adjuvant 
 Dynamic marker-Adjusted Personalized Therapy) trial opti-
mizes risk assessment and therapy response prediction in 
early breast cancer as an umbrella program for all tumor sub-
types and GeparSepto in the neoadjuvant setting compares 
nanoparticle-based paclitaxel with solvent-based paclitaxel 
and the use of pertuzumab in combination with trastuzumab 
in the HER2+ subgroup. In metastatic breast cancer a focus is 
on the DETECT III study, which randomizes HER2+ CTCs 
to treat these patients with chemotherapy ± lapatinib.
Liedtke: It is difficult, if not impossible to single out one or 
two clinical trials from the plethora of studies presented at 
this year’s SABCS. As could be expected a large number of 
trials focused on the optimal use of HER2 targeted agents 
evaluating the optimal agents or combinations thereof, opti-
mal duration and optimal scheduling / sequence. One trial I 
would like to point out in this context is the NSABP B43 trial 
which was presented by Cobleigh et al. and which is currently 
being conducted among patients with HER2+ DCIS. The 
 Investigators evaluate whether radiotherapy in combination 
with trastuzumab decreases ipsilateral breast cancer recur-
rence, ipsilateral skin cancer recurrence, or ipsilateral DCIS 
recurrence. The target accrual is set at 2,000 patients. Also, 
given the controversial results of the German SENTINA 
study and the American ACOSOG Z1071 study, the results of 
the French GANEA II study are awaited with interest. This 
study largely resembles the ACOSOG Z1071 trial and will 
 accrue 858 patients (Classe et al.).
Rack: Most interesting in my opinon are the DETECT study 
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gional recurrence, however, a clear benefit of this approach 
has not yet been demonstrated. Aebi et al. randomized 162 
women to either adjuvant chemotherapy or none upon diag-
nosis and resection of locoregional recurrence. Thereby, the 
authors could demonstrate an improvement of 5-year DFS 
rate from 57 to 69% (p = 0.0455). The authors of this study 
should be congratulated for demonstrating these clinically 
highly relevant results, however, additional studies will be 
needed analyzing which regimens best be used in this setting 
(Aebi et al.).
Rack: The CALOR trial could show that patients with iso-
lated local or regional recurrence benefit from chemotherapy, 
especially if they are ER–. This finding is clinically very 
 relevant, however, the trial accrued only a limited number of 
patients and had to be closed early. An updated analysis of 
the TARGIT A trial after a median follow up of 5 years 
showed that more local recurrences occurred with intraopera-
tive  radiotherapy, however, more deaths due to other cancers 
and cardiovascular events with external beam radiotherapy. 
The START B trial could show that hypofractionated irradia-
tion (15 fractions) is equivalent to 25 fractions.
Steger: The Austrian data on the value of a genomic assay for 
the prediction of late recurrences in patients with hormone-
sensitive breast cancer are really interesting, in particular in 
the context of the results of the ATLAS trial showing the 
 benefits from tamoxifen use over 10 years. This assay may 
also give important information about adjuvant aromatase 
 inhibitors but the results from these studies are not available 
yet. The results of the CALOR trial dealing with adjuvant 
chemotherapy after local recurrences are for sure very im-
portant. Even though this trial is small and took a long time 
for recruitment, the data show a clear DFS benefit at 5 years 
for those patients having received the adjuvant intervention. 
I  really do think that these results must lead to a large interna-
tional study to clarify this important question. I think, for the 
time being, patients after local recurrences should be offered 
appropriate systemic therapy including chemotherapy based 
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